Tonix Pharmaceuticals Holding Corp [NASDAQ: TNXP] traded at a low on 2025-08-18, posting a -21.97 loss after which it closed the day’ session at $40.07.
The results of the trading session contributed to over 7904286 shares changing hands. Over the past one week, the price volatility of Tonix Pharmaceuticals Holding Corp stands at 25.47% while the volatility over the past one month is 13.51%.
The market cap for TNXP stock reached $351.25 million, with 8.77 million shares outstanding and 8.76 million shares in the current float. Compared to the average trading volume of 1.35M shares, TNXP reached a trading volume of 7904286 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Tonix Pharmaceuticals Holding Corp [TNXP]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TNXP shares is $61.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TNXP stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Noble Capital Markets have made an estimate for Tonix Pharmaceuticals Holding Corp shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 18, 2022. The new note on the price target was released on April 18, 2019, representing the official price target for Tonix Pharmaceuticals Holding Corp stock. Previously, the target price had yet another raise to $6, while ROTH Capital analysts kept a Buy rating on TNXP stock.
The Price to Book ratio for the last quarter was 1.80, with the Price to Cash per share for the same quarter was set at 14.30.
How has TNXP stock performed recently?
Tonix Pharmaceuticals Holding Corp [TNXP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.90. With this latest performance, TNXP shares dropped by -14.58% in over the last four-week period, additionally plugging by 235.31% over the last 6 months – not to mention a rise of 21.50% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TNXP stock in for the last two-week period is set at 43.81, with the RSI for the last a single of trading hit 7.95, and the three-weeks RSI is set at 5.87 for Tonix Pharmaceuticals Holding Corp [TNXP]. The present Moving Average for the last 50 days of trading for this stock 41.59, while it was recorded at 54.47 for the last single week of trading, and 26.86 for the last 200 days.
Tonix Pharmaceuticals Holding Corp [TNXP]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Tonix Pharmaceuticals Holding Corp [TNXP] shares currently have an operating margin of -838.00% and a Gross Margin at 9.22%. Tonix Pharmaceuticals Holding Corp’s Net Margin is presently recorded at -828.22%.
Tonix Pharmaceuticals Holding Corp (TNXP) Capital Structure & Debt Analysis
According to recent financial data for Tonix Pharmaceuticals Holding Corp. ( TNXP), the Return on Equity (ROE) stands at -77.51%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -63.20%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Tonix Pharmaceuticals Holding Corp’s Return on Invested Capital (ROIC) is -48.38%, showcasing its effectiveness in deploying capital for earnings.
Tonix Pharmaceuticals Holding Corp (TNXP) Efficiency & Liquidity Metrics
Based on Tonix Pharmaceuticals Holding Corp’s (TNXP) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Tonix Pharmaceuticals Holding Corp (TNXP) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Tonix Pharmaceuticals Holding Corp. (TNXP) effectively leverages its workforce, generating an average of -$1005185.19 per employee. The company’s liquidity position is robust, with a Current Ratio of 7.53% and a Quick Ratio of 7.22%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Tonix Pharmaceuticals Holding Corp [TNXP]
With the latest financial reports released by the company, Tonix Pharmaceuticals Holding Corp posted -25.56/share EPS, while the average EPS was predicted by analysts to be reported at -736/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 710.44. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TNXP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Tonix Pharmaceuticals Holding Corp go to 88.07%.
Insider trade positions for Tonix Pharmaceuticals Holding Corp [TNXP]
There are presently around $16.03%, or 16.04%% of TNXP stock, in the hands of institutional investors. The top three institutional holders of TNXP stocks are: PRUDENTIAL FINANCIAL INC with ownership of 97707.0 shares, which is approximately 0.0239%. ALYESKA INVESTMENT GROUP, L.P., holding 62500.0 shares of the stock with an approximate value of $$43588.0 in TNXP stocks shares; and ALYESKA INVESTMENT GROUP, L.P., currently with $$39000.0 in TNXP stock with ownership which is approximately 0.0141%.
